• Isoproterenol Sulfate Dihydrate in SAN Assays

  2026-08-14

  Use Isoproterenol sulfate dihydrate to turn human SAN–cardiac plexus assembloids into a controlled test of acute β-adrenergic responsiveness. A defined agonist challenge can separate receptor-driven rate modulation from deeper pacemaker maturation and neuro-cardiac organization.

• 6-Thioguanine Blocks EV71 via BIRC3-Linked Autophagy

  2026-08-14

  A 2025 BMC Microbiology study identifies 6-thioguanine as a potent in vitro inhibitor of Enterovirus 71 replication and links this activity to reduced BIRC3 expression and incomplete autophagy. The work provides a mechanistic framework for antiviral drug repurposing while highlighting the need for validation in additional models and clinically relevant settings.

• AICAR Phosphate: AMPK Logic for Translational Research

  2026-08-13

  AICAR phosphate (Acadesine) offers a practical way to interrogate how AMPK activation reshapes apoptosis, mitochondrial quality control, and inflammatory signaling. This thought-leadership guide connects B-CLL cancer research with emerging mechanobiology while emphasizing model-specific validation, assay design, and translational limits.

• HSP90 Regulation of RNA Foci in DM1

  2026-08-13

  A microscopy-based small-molecule screen identified HSP90 as a differentiation-dependent regulator of DMPK mRNA and toxic CUG-repeat RNA foci in myotonic dystrophy type 1 cells. Genetic validation and pathway analysis connected HSP90 activity to p-STAT3 in undifferentiated myoblasts, while differentiated cells showed an opposite, p-STAT3-independent response.

• TSA and Osseointegration in Osteoporotic Rats

  2026-08-12

  A Scientific Reports study found that Trichostatin A improved titanium-rod osseointegration in ovariectomized osteoporotic rats by reducing oxidative stress and activating AKT/Nrf2 signaling. The work connects HDAC inhibition with mitochondrial protection, osteogenic differentiation, and implant integration, while remaining a preclinical mechanistic study.

• PR-619: Practical DUB Inhibition Workflows

  2026-08-12

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for mapping ubiquitin-dependent biology without directly blocking proteasomal catalysis. This guide covers stock preparation, dose-finding, autophagy and cytotoxicity assays, and a hypothesis-driven framework for connecting DUB perturbation with progenitor exhausted T-cell research.

• MAPK10–KRT16 Axis Suppresses NSCLC Metastasis

  2026-08-11

  The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical evidence positions the MAPK10/KRT16/RNF213 axis as a mechanistic biomarker framework, while also highlighting the need for larger and more specific validation studies.

• MK-4827 (Niraparib) for PARP Research

  2026-08-10

  MK-4827 (Niraparib) provides a practical way to model selective PARP-1/-2 inhibition across BRCA-deficient, DNA repair–altered, and radiosensitization workflows. This guide connects compound handling and assay design with emerging evidence that spliceosome regulation can reshape PARP inhibitor sensitivity in hepatocellular carcinoma.

• Cy5 NHS ester(Et): Practical Labeling Guide

  2026-08-09

  Cy5 NHS ester(Et) is a water-soluble amine-reactive reagent for covalently tagging proteins, peptides, and other biomolecules in fluorescence workflows. It is suited to immediate-use aqueous labeling for immunofluorescence, flow cytometry, and microscopy, but should not be selected for ethanol-based protocols or long-term storage of working solutions.

• Dabigatran Etexilate: Clinical Review and Evidence

  2026-08-08

  This clinical review examines dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its prodrug design, predictable pharmacology, clinical efficacy, tolerability, and renal dosing considerations. Its main practical significance is the possibility of oral anticoagulation without the routine INR-centered management required for vitamin K antagonists, although bleeding risk and renal function remain central limitations.

• Lypressin Acetate: Workflows for GPCR Research

  2026-08-07

  Lypressin acetate connects vasopressin-receptor signaling, antidiuretic biology, and vasoconstriction research in one peptide workflow. This practical guide covers assay setup, quantitative controls, exploratory SARS-CoV-2 studies, and troubleshooting for more reproducible results.

• Refined Jiawei-Xiaoyao Formula: Rapid Antidepressant Action

  2026-08-07

  This study identifies a minimal, three-herbal combination (GMA) derived from the traditional Jiawei-Xiaoyao Pill that delivers rapid antidepressant-like effects in a mouse model of LPS-induced depression. The research elucidates how GMA modulates neuroinflammation and neuroplasticity signaling pathways, establishing mechanistic insight into its efficacy and informing rational refinement of traditional herbal interventions.

• Ceruletide in Pancreatic Function Research: Protocols & Pitf

  2026-08-06

  Ceruletide (Caerulein) enables precise modeling of pancreatic fibrosis and gastrointestinal physiology for both bench and translational research. This guide details optimized protocols, troubleshooting strategies, and practical insights inspired by the latest autophagy-modulation findings.

• O-GlcNAcylation Drives Wnt-Linked Bone Formation via Glycoly

  2026-08-06

  This study uncovers how Wnt signaling stimulates bone formation through rapid and sustained increases in O-GlcNAcylation, which in turn rewires glycolytic metabolism in osteoblasts. The findings establish O-GlcNAcylation as an indispensable mediator of Wnt-induced osteogenesis and offer new mechanistic insights relevant for metabolic bone disease research.

• Reliable mTOR Inhibition: Everolimus (RAD001) in Cancer Assa

  2026-08-05

  This article guides biomedical researchers and laboratory teams through real-world challenges in cell viability, proliferation, and cytotoxicity assays using Everolimus (RAD001), SKU A8169. It explores workflow optimizations, protocol parameters, and vendor selection, emphasizing reproducibility and data-backed decision-making. Evidence from peer-reviewed studies and product analytics support the use of APExBIO's Everolimus (RAD001) for robust cancer research.

437 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page